Literature DB >> 2183595

Recurrent spleen enlargement during cyclic granulocyte-macrophage colony-stimulating factor therapy for myelodysplastic syndrome.

A Delmer1, M Karmochkine, M Cadiou, H Gerhartz, R Zittoun.   

Abstract

A 65-year-old woman with refractory anemia with excess of blasts received sequential courses of granulocyte-macrophage colony-stimulating factor therapy (GM-CSF) and low-dose cytosine arabinoside. Each course of GM-CSF induced a rapid and tremendous increase in leukocyte count as well as in spleen size, 111indium chloride scanning suggested a myeloid metaplasia of the spleen. This observation suggests that in some patients the granulopoietic response to the myeloid growth factor stimulation may be predominant in the spleen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2183595     DOI: 10.1002/ajh.2830340117

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

2.  Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression.

Authors:  Helena Lund-Palau; Claudia Ivette Juarez-Molina; Cuixiang Meng; Anushka Bhargava; Aikaterini Pilou; Kiran Aziz; Nora Clarke; Naoko Atsumi; Ali Ashek; Michael R Wilson; Masao Takata; Simon Padley; Deborah R Gill; Stephen C Hyde; Cliff Morgan; Eric W F W Alton; Uta Griesenbach
Journal:  Mol Ther Methods Clin Dev       Date:  2022-04-14       Impact factor: 5.849

3.  Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.

Authors:  H H Gerhartz; R Marcus; A Delmer; H Zwierzina; T de Witte; A Jacobs; G Visiani; D Fiere; P Sonneveld; B Labar
Journal:  Infection       Date:  1992       Impact factor: 3.553

4.  Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson's disease.

Authors:  Katherine E Olson; Krista L Namminga; Yaman Lu; Mackenzie J Thurston; Aaron D Schwab; Seymour de Picciotto; Sze-Wah Tse; William Walker; Jared Iacovelli; Clayton Small; Brian T Wipke; R Lee Mosley; Eric Huang; Howard E Gendelman
Journal:  Biomaterials       Date:  2021-03-31       Impact factor: 12.479

5.  Neuroprotective Activities of Long-Acting Granulocyte-Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice.

Authors:  Katherine E Olson; Krista L Namminga; Aaron D Schwab; Mackenzie J Thurston; Yaman Lu; Ashley Woods; Lei Lei; Weijun Shen; Feng Wang; Sean B Joseph; Howard E Gendelman; R Lee Mosley
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 6.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.